BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives $401.00 Average PT from Analysts

Shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) have earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $389.1818.

Several research analysts have recently commented on ONC shares. Morgan Stanley reiterated an “overweight” rating and set a $405.00 target price on shares of BeOne Medicines in a research note on Thursday, January 8th. Jefferies Financial Group downgraded BeOne Medicines from a “buy” rating to a “hold” rating and cut their price target for the company from $420.00 to $290.00 in a report on Monday. Royal Bank Of Canada lifted their price objective on shares of BeOne Medicines from $417.00 to $425.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Wall Street Zen downgraded shares of BeOne Medicines from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Finally, Sanford C. Bernstein raised shares of BeOne Medicines from a “hold” rating to an “outperform” rating and set a $414.00 price objective on the stock in a research report on Monday, January 12th.

BeOne Medicines Stock Up 0.2%

Shares of ONC stock opened at $282.72 on Friday. BeOne Medicines has a 52-week low of $196.45 and a 52-week high of $385.22. The stock has a market cap of $31.00 billion, a price-to-earnings ratio of 112.19 and a beta of 0.53. The firm’s 50-day moving average is $331.46 and its 200-day moving average is $329.06. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.08 and a current ratio of 3.41.

BeOne Medicines (NASDAQ:ONC) last announced its quarterly earnings results on Thursday, February 26th. The company reported $0.58 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($1.02). The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.45 billion. BeOne Medicines had a return on equity of 10.70% and a net margin of 5.37%. Sell-side analysts predict that BeOne Medicines will post -5.82 EPS for the current year.

Insider Buying and Selling

In other BeOne Medicines news, SVP Chan Henry Lee sold 1,660 shares of the stock in a transaction dated Wednesday, February 4th. The shares were sold at an average price of $349.52, for a total value of $580,203.20. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In the last quarter, insiders have sold 2,665 shares of company stock valued at $902,792. 6.62% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On BeOne Medicines

Several institutional investors and hedge funds have recently made changes to their positions in the company. ProShare Advisors LLC acquired a new stake in BeOne Medicines during the 2nd quarter worth approximately $373,000. KBC Group NV acquired a new position in BeOne Medicines in the 2nd quarter valued at $2,175,000. PNC Financial Services Group Inc. acquired a new position in BeOne Medicines in the 2nd quarter valued at $228,000. Geode Capital Management LLC bought a new position in BeOne Medicines during the 2nd quarter worth $8,622,000. Finally, Fiera Capital Corp acquired a new stake in shares of BeOne Medicines during the second quarter worth $5,062,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.